Alamar Biosciences reported a sharp revenue rebound in its first full quarter as a public company, alongside an expansion of a large-scale plasma proteomics collaboration tied to Alzheimer’s. In Q2 2026, Alamar’s revenue rose 81% year over year to $29.4 million, driven by nearly doubled product revenue and growth in instruments and consumables. The company forecast 2026 revenue of $116 million to $120 million at midpoint, projecting 59% growth. Separately, Alamar said it expanded its partnership with the Alzheimer’s Disease Data Initiative and Gates Ventures to analyze an additional 86,000 plasma samples using its NULISAseq Neuro 220 neurology panel, pushing the total analyzed samples to more than 140,000. The expanded dataset is intended to pair multiplex protein profiling with deep clinical phenotyping to capture variation across individuals and populations. —